Media
RxMP Therapeutics Announces Opening of $2 Million Bridge Financing Round
RxMP Therapeutics is announcing the opening of a $2 million bridge financing round to support the next phase of development for its lead hemostatic platform. The round already has over $1.2M committed, led by a $750,000 investment from the Wallace H. Coulter Foundation, the company’s largest shareholder and long-time partner. This strong early support, including additional investment in this round by insiders, underscores continued confidence in RxMP’s mission and progress toward delivering a life-saving hemorrhage control solution.
RxMP Press Release for Monday, June 9th, 2025
Enters Into Research & Development Agreement with Department of Defense’s Institute of Surgical Research
Reaches Consensus with FDA on GMP Allogeneic Manufacturing Process of RMP-402
Appoints Shawna Khouri as Chief Operating Officer